News

1/04

Landos Biopharma Announces Positive Results from a Phase 2 Trial of Oral BT-11 for Patients with Ulcerative Colitis

Read More

7/14

Landos Biopharma Announces First Human Dosing in a Phase 1 Study of NX-13, its Novel Candidate for Inflammatory Bowel Disease

Read More

5/12

Landos Biopharma to Present at Two Upcoming Investor Conferences

Read More

3/24

Landos Biopharma to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference

Read More

2/26

Landos Biopharma to Present at the Cowen and Company 40th Annual Health Care Conference

Read More

1/09

Landos Biopharma to Present at the 38th Annual J.P. Morgan Healthcare Conference

Read More